Breaking News

Kindeva Secures $129M SNS Contract for Nerve Agent Antidote

The treatment will be stockpiled and available for rapid deployment as part of the SNS CHEMPACK program.

Author Image

By: Charlie Sternberg

Associate Editor

Kindeva Drug Delivery’s global health security division, Meridian Medical Technologies, LLC, has secured a contract valued at up to $129 million to supply DuoDote, a chemical nerve agent antidote autoinjector, to the Strategic National Stockpile (SNS), managed by the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. DuoDote is an FDA-approved dual-chamber autoinjector, containing atropine and pralidoxime chloride, and is ind...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters